GlassScriptPhysician profile
Bryan Anthony Hubl
NPI 1700867892
$2,322.93
in general payments reported to CMS, 2019-2025
29 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $318 · 2021: $348 · 2022: $534 · 2023: $315 · 2024: $230 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $801.62 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $214.99 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $185.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.06 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.46 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $91.46 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $85.17 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.49 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $80.66 | 2019-2021 | |
| Lilly USA, LLC | $77.37 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $43.76 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $37.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.04 | 2024-2025 | Xifaxan |
| Sanofi Pasteur INC. | $29.97 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.30 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $26.74 | 2025 | Sprint Pns System |
| Paratek Pharmaceuticals, INC. | $26.11 | 2020-2022 | |
| Scpharmaceuticals INC. | $23.25 | 2024 | |
| Seqirus USA INC | $21.98 | 2025 | Fluad, Flucelvax |
| Allergan, INC. | $18.69 | 2019 | |
| Novo Nordisk INC | $18.49 | 2023 | Rybelsus, Ozempic |
| Melinta Therapeutics, LLC | $16.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.09 | 2021 | |
| Electromed, INC. | $15.81 | 2022 | |
| Exact Sciences Corporation | $15.22 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $15.09 | 2025 | Yupelri |
| Baxter Healthcare | $13.90 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $13.01 | 2022 | |
| Boston Scientific Corporation | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Hubl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.